Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2009-03-06
2010-12-21
Yu, Misook (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S133100
Reexamination Certificate
active
07855275
ABSTRACT:
Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I:in-line-formulae description="In-line Formulae" end="lead"?Ab-(L-D)p Iin-line-formulae description="In-line Formulae" end="tail"?where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.
REFERENCES:
patent: 5219996 (1993-06-01), Bodmer et al.
patent: 6248564 (2001-06-01), Walter et al.
patent: 6753165 (2004-06-01), Cox et al.
patent: 7097840 (2006-08-01), Erickson et al.
patent: 2004/0005324 (2004-01-01), Pilkington et al.
patent: 2004/0229310 (2004-11-01), Simmons
patent: 2004/0235068 (2004-11-01), Levinson
patent: 2005/0048572 (2005-03-01), Reilly et al.
patent: 89/01974 (1989-03-01), None
patent: 94/06474 (1994-03-01), None
patent: 03/049704 (2003-06-01), None
patent: 03/060080 (2003-07-01), None
patent: 2004/050849 (2004-06-01), None
All drugs online. Retrieved from the Internet >URL: http://www.all-drugs-online.com/Drugs/Oncology/1377.aspx> Retrieved on Jan. 5, 2009.
Baca et al., “Antibody Humanization Using Monovalent Phage Display”Journal of Biological Chemistry272(16):10678-10684 (1997).
Bernhard et al., “Cysteine analogs of recombinant barley ribosome inactivating protein form antibody conjugates with enhanced stability and potency in vitro”Bioconjug Chem.(5) 2:126-132 (Mar. 1994).
Better et al., “Gelonin analogs with engineered cysteine residues form antibody immunoconjugates with unique properties”J Biol Chem.269 (13):9644-9650 (Apr. 1, 1994).
Biopharma. Retrieved from the Internet >URL: http://www.biopharma.com/Samples/184.html> Retrieved on Jan. 5, 2009.
Carter et al., “Humanization of an Anti-p185HER2Antibody For Human Cancer Therapy”Proc Natl Acad Sci U S A.89(10) :4285-4289 (May 1992).
CellTiter-Glo Luminescent Cell Viability Assay(Technical Bulletin No. 288), Madison, WI:Promega Corp., pp. 1-11 (Feb. 2004).
Chang et al., “High-Level Secretion of Human Growth Hormone byEscherichia coli” Gene55:189-196 (1987).
Chmura et al., “Antibodies with infinite affinity”Proc Natl Acad Sci U S A.98(15):8480-8484. (Jul. 17, 2001).
Collaborative Computational Project, No. 4, “The CCP4 Suite: Programs for Protein Crystallography”Acta. Cryst.D50:760-763 (1994).
Corneillie et al, “Converting Weak Binders into Infinite Binders”Bioconjugate Chem.15(6):1389-1391 (2004).
Dennis et al., “Albumin binding as a general strategy for improving the pharmacokinetics of proteins”Journal of Biological Chemistry277(38) :35035-35043 (Sep. 20, 2002).
Doronina et al., “Development of potent monoclonal antibody auristatin conjugates for cancer therapy”Nature Biotechnology21:778-784 (2003).
Eigenbrot et al., “X-Ray Structures of the Antigen-Binding Domains From Three Variants of Humanized Anti-p185HER2Antibody 4D5 and Comparison With Molecular Modeling”J. Mol. Biol.229:969-995 (1993).
Gerstner et al., “Sequence Plasticity in the Antigen-binding Site of a Therapeutic Anti-HER2 Antibody”J. Mol. Biol.321:851-862 (2002).
Greenwood et al., “Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis”Therapeutic Immunology1(5) :247-255 (Oct. 1994).
Hafner et al., “Noncompetitive Immunoassay of Small Analytes at the Femtomolar Level by Affinity Probe Capillary Electrophoresis: Direct Analysis of Digoxin Using a Uniform-Labeled scFv Immunoreagent”Anal. Chem72(23):5779-5786 (Dec. 1, 2000).
Ho et al., “Site-Directed Mutagenesis by Overlap Extension Using the Polymerase Chain Reaction”Gene77(1):51-59 (1989).
Ito et al., “A general method for introducing a series of mutations into cloned DNA using the polymerase chain reaction”Gene102(1) :67-70 (Jun. 15, 1991).
Junutula et al., “Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs”J Immunol Methods332:41-52 (2008).
Kabat et al., “Sequences of Proteins of Immunological Interest”US Department of Health and Human Services, Public Health Service, NIH, 4th edition pp. 160 and 294 (1987).
Kanno et al., “Assembling of engineered IgG-binding protein on gold surface for highly oriented antibody immobilization”J Biotechnol.76(2-3):207-214 (Jan. 21, 2000).
King et al., “Facile synthesis of maleimide bifunctional linkers”Tetrahedron Letters43:1987-1990 (2002).
Lambert, J, “Drug-conjugated monoclonal antibodies for the treatment of cancer”Curr Opin Pharmacol.5(5):543-549 (Oct. 2005).
Lewis et al., “Maleimidocysteineamido-DOTA derivatives: new reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions”Bioconjug Chem.9(1) :72-86 (Jan. 1998).
Lowman, H., “Phage display of peptide libraries on protein scaffolds”Methods in Molecular Biology, Chapter 24, 87:249-264 (1998).
Lund et al., “Expression and characterization of truncated forms of humanized L243 IgG1. Architectural features can influence synthesis of its oligosaccharide chains and affect superoxide production triggered through human Fcgamma receptor I”Eur J Biochem.267(24) :7246-7257 (Dec. 2000).
MacCallum, R. M. et al., “Antibody-antigen interactions: contact analysis and binding site topography”J. Mol. Biol.262:732-745 (1996).
Olafsen et al., “Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting”Protein Eng Des Sel.17(4) :315-323 (Apr. 2004).
Payne, Gillian, “Progress in Immunoconjugate Cancer Therapeutics”Cancer Cell3:207-212 (2003).
Renard et al., “Deriving Topological Constraints from Functional Data for the Design of Reagentless Fluorescent Immunosensors”J. Mol. Biol.326:167-175 (2003).
Roux et al., “Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immunue complexes: a role for flexibility and geometry”J Immunol.161(8) :4083-4090 (Oct. 15, 1998).
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity”Proc. Natl. Acad Sci. USA79:1979-1983 (Mar. 1982).
Schelte et al, “Differential Reactivity of Maleimide and Bromoacetyl Functions with Thiols: Application to the Preparation of Liposomal Diepitope Constructs”Bioconjugate Chem11:118-123 (2000).
Senter et al., “Immunoconjugates comprised of drugs with impaired cellular permeability: a new approach to targeted therapy, Abstract No. 623, presented on Mar. 28, 2004, Proceedings of the American Association for Cancer Research” 45:36 (2004).
Shopes, “A Genetically Engineered Human IgG With Limited Flexibility Fully Initiates Cytolysis Via Complement”Molecular Immunology30(6):603-609 (1993).
Singh et al., “Labeling of antibodies by in situ modification of thiol groups generated from selenol-catalyzed reduction of native disulfide bonds”Analytical Biochemistry304(2):147-156 (May 15, 2002).
Stimmel et al., “Site-specific Conjugation on Serine—Cysteine Variant Monoclonal Antibodies”Journal of Biological Chemistry275(39):30445-50 (Sep. 29, 2000).
Sun et al., “Enabling ScFvs as multi-drug carriers: a dendritic approach”Bioorg Med Chem.11(8) :1761-1768 (Apr. 17, 2003).
Sun et al., “Synth
Eigenbrot Charles W.
Junutula Jagath Reddy
Lowman Henry
Raab Helga E.
Vandlen Richard
Andrus Alex
Genentech Inc.
Genentech, Inc.
Natarajan Meera
Yu Misook
LandOfFree
Cysteine engineered antibodies and conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cysteine engineered antibodies and conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cysteine engineered antibodies and conjugates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4236215